Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7350919 | 1.00 | KMT2A (0.41) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL201249 | 1.00 | KMT2A (0.41) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5224314 | 0.98 | — | — | |
| SCHEMBL11122946 | 0.98 | — | — | |
| SCHEMBL3361966 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL6395633 | 0.94 | KMT2A (0.40) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL6392619 | 0.94 | KMT2A (0.40) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL2675695 | 0.82 | KMT2A (0.40) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5362921 | 0.82 | KMT2A (0.40) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28052844 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109574953-A | A kind of preparation method of 4-thiazolecarboxylic acid | 江苏诺恩作物科学股份有限公司 | 2019-04-05 | — | — | CN | claimed |
| US-11505617-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108727407-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-105198908-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2018-12-13 | — | — | US | disclosed |
| EP-3100745-B1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-1963262-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007069020-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-0091525-A2 | Phosphonoalkanoylamino acids | ANALYTICAL RESEARCH PHARMACEUTICALS PTY. LTD. (AU) | 1983-10-19 | — | — | EP | disclosed |
| US-4374249-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1983-02-15 | — | — | US | disclosed |
| EP-0070131-A1 | Phosphonoalkanoylamino acids | ANALYTICAL RESEARCH PHARMACEUTICALS PTY. LTD. (AU) | 1983-01-19 | — | — | EP | disclosed |
| US-4316896-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0009183-B1 | PHOSPHORYL AMINOACID DERIVATIVES AND COMPOSITION FOR TREATING HYPERTENSION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1981-10-21 | — | — | EP | disclosed |
| US-4066749-A | Tetrapeptide analog of TRH | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CHRNB4 132/4885CHRNA3 44/4885CHRNA7 73/4885 |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CHRNB4 132/4885CHRNA3 44/4885CHRNA7 73/4885 |
| US-10208127-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | CHRNB4 115/4885CHRNA3 37/4885CHRNA7 66/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CHRNB4 132/4885CHRNA3 44/4885CHRNA7 73/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | CHRNB4 132/4885CHRNA3 44/4885CHRNA7 73/4885 |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | CHRNB4 4859/4885CHRNA3 4816/4885CHRNA7 4814/4885 |
| US-11505617-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | CHRNB4 115/4885CHRNA3 37/4885CHRNA7 66/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | CHRNB4 115/4885CHRNA3 37/4885CHRNA7 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.